Evidence map›Paper›PMID 21950318›Full record

ArticleAutoimmunity2012

Myasthenogenicity of the main immunogenic region and endogenous muscle nicotinic acetylcholine receptors.

Jie Luo, Jon Lindstrom

Abstract read
In one paragraph

Article in Autoimmunity, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 25 citations in OpenAlex.

  1. Neonatal Fc Receptor-Targeted Therapies in Neurology.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022
    Review
  2. Narrative review of immunotherapy in thymic malignancies.Translational lung cancer research · 2021
    Review
  3. Article
  4. Advances in autoimmune myasthenia gravis management.Expert review of neurotherapeutics · 2018
    Review
  5. Review
  6. Article
  7. Article
  8. Myasthenogenicity of the main immunogenic region.Annals of the New York Academy of Sciences · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jie LuoDepartment of Neuroscience, University of Pennsylvania Medical School, Philadelphia, PA 19104-6074, USA.
Jon Lindstrom
University of Pennsylvania · US

Funding

STUDIES USING PURIFIED ACETYLCHOLINE RECEPTORSR01NS011323 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI LINDSTROM, JON MARTIN · 1985 to 2012
$5.0M
EAMG: MIR structure and specific immunosuppressive therapyR01NS052463 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI LINDSTROM, JON MARTIN · 2006 to 2009
$1.7M
NINDS NIH HHS NS052463NINDS NIH HHS NS11323NINDS NIH HHS R01 NS011323NINDS NIH HHS R01 NS052463
6 · The paper itself

Abstract

In myasthenia gravis (MG) and experimental autoimmune MG (EAMG), many pathologically significant autoantibodies are directed at the main immunogenic region (MIR), a conformation-dependent region at the extracellular tip of α1 subunits of muscle nicotinic acetylcholine receptors (AChRs). Human muscle AChR α1 MIR sequences were integrated into Aplysia ACh-binding protein (AChBP). The chimera was potent in inducing both acute and chronic EAMG, though less potent than Torpedo electric organ AChR. Wild-type AChBP also induced EAMG but was less potent, and weakness developed slowly without an acute phase. AChBP is more closely related in sequence to neuronal α7 AChRs that are also homomeric; however, autoimmune responses were induced to muscle AChR, but not to neuronal AChR subtypes. The greater accessibility of muscle AChRs to antibodies, compared to neuronal AChRs, may allow muscle AChRs to induce self-sustaining autoimmune responses. The human α1 subunit MIR is a potent immunogen for producing pathologically significant autoantibodies. Additional epitopes in this region or other parts of the AChR extracellular domain contribute significantly to myasthenogenicity. We show that an AChR-related protein can induce EAMG. Thus, in principle, an AChR-related protein could induce MG. AChBP is a water-soluble protein resembling the extracellular domain of AChRs, yet rats that developed EAMG had autoantibodies to AChR cytoplasmic domains. We propose that an initial autoimmune response, directed at the MIR on the extracellular surface of muscle AChRs, leads to an autoimmune response sustained by muscle AChRs. Autoimmune stimulation sustained by endogenous muscle AChR may be a target for specific immunosuppression.

Indexed as

AnimalsAntibody SpecificityAutoantibodiesCell LineCross ReactionsFemaleHumansMusclesMyasthenia Gravis, Autoimmune, ExperimentalNeuronsRatsReceptors, NicotinicAutoantibodiesReceptors, Nicotinic

Identifiers

PMID21950318
PMCPMC3250566
OpenAlexW1968206925

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.